<DOC>
	<DOCNO>NCT02985125</DOCNO>
	<brief_summary>This study single-arm , open-label , multi-institutional Phase I/II trial combination LEE011 everolimus refractory mPAC .</brief_summary>
	<brief_title>LEE011 Plus Everolimus Patients With Metastatic Pancreatic Adenocarcinoma Refractory Chemotherapy</brief_title>
	<detailed_description>This single arm , open label Phase I/II study evaluate progression free survival 8 week ( PFS8week ) combination LEE-011 plus everolimus , patient metastatic pancreatic cancer refractory 5-fluorouracil ( 5-FU ) gemcitabine-based chemotherapy . Previous study third-line therapy mPAC limit reveal stable disease 25-31 % patient partial complete response ( 31 % patient GVAX/CRS-207 combination vaccine study stable disease 52 % patient treat third-line setting ) . It hop combination LEE-011 plus everolimus increase PFS8weeks least 50 % , though early stopping rule place lack efficacy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically confirm mPAC ( mixed histology acceptable long predominant histology pancreatic adenocarcinoma ) 2 . Patient must consent two mandatory biopsy tumor amenable biopsy 3 . Measurable disease RECIST v1.1 criterion ( tumor ≥ 1 cm long diameter axial image CT MRI and/or lymph node ( ) ≥ 1.5 cm short axis CT MRI ) baseline image 4 . Documented progression disease least one 5FUbased regimen least one GEMbased regimen metastatic disease ( progression within 3 month completion adjuvant therapy acceptable ) 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 ( see Table 2 ) 6 . Age ≥ 18 year 7 . Subjects brain metastasis history previously treat brain metastasis treat surgery stereotactic radiosurgery ( SRS ) least 4 week prior enrollment baseline MRI show evidence active intracranial disease 8 . Patients available standard 12lead ECG follow parameter screen ( define mean triplicate ECGs ) : QTcF interval screen &lt; 450msec Resting heart rate 5090bpm 9 . Bone marrow function : absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; Platelets ≥100 × 109/L ; hemoglobin ≥ 9.0 g/dL • Patients may transfusion red blood cell meet hemoglobin requirement 10 . Renal function : serum creatinine ≤ 1.5 × upper normal limit institution 's normal range creatinine clearance ≥ 50 mL/min/1.73 m2 subject creatinine level institutional normal 11 . Hepatic function : Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 3.0 × upper normal limit institution 's normal range . Total bilirubin ≤ 1.5 × upper normal limit institution 's normal range . For subject liver metastasis , AST ALT &lt; 5 × upper normal limit institution 's normal range , total bilirubin &gt; 1.5 3.0 x upper normal limit institution 's normal range acceptable long persistent nausea , vomit , right upper quadrant pain tenderness , fever , rash , eosinophilia . 12 . Partial Thromboplastin Time ( PTT ) must ≤ 1.5 × upper normal limit institution 's normal range International Normalized Ratio ( INR ) &lt; 1.5 . Subjects anticoagulant ( warfarin ) permit enroll long INR acceptable therapeutic range determine investigator . 13 . Potassium , total calcium ( correct serum albumin ) , magnesium , sodium phosphorus within normal limit institution correct within normal limit supplement first dose study medication 14 . Patients must fully recover effect surgery . Patients must least two week minor surgery four week major surgery start therapy . Minor procedure require `` Twilight '' sedation endoscopy mediport placement may require 24hour wait period , must discuss investigator . 15 . Women childbearing potential must negative serum pregnancy test within 14 day prior initiation treatment and/or postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential 16 . Patient capable swallow pill whole 17 . Patient capable understand comply parameter outline protocol able sign date inform consent , approve Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure 1 . Patients previously expose , intolerant , ineligible Cyclindependent kinase ( CDK ) inhibitor , Mammalian target rapamycin ( mTOR ) inhibitor , and/or combination 2 . Prior antitumor therapy within 3 week Cycle 1 Day 1 ( antitumor therapy define , limited , anticancer agent ( cytotoxic chemotherapy , immunotherapy , biologic therapy ) , radiotherapy , investigational agent ) , `` washout period '' 3 . Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , cause unacceptable safety risk , contraindicate patient participation clinical study compromise compliance protocol ( e.g . chronic pancreatitis , chronic active hepatitis , active untreated uncontrolled fungal , bacterial viral infection , etc. ) . 4 . Women pregnant breastfeed 5 . Concurrent use CYP3A4 inhibit activate medication 6 . Concurrent use Angiotensinconverting enzyme ( ACE ) inhibitor ( increase risk angioedema ACE inhibitor administer combination everolimus , see approximately 6.8 % patient ) 7 . Psychiatric illness social situation would limit compliance study requirement 8 . Patient concurrent malignancy malignancy within 3 year prior start study drug , exception adequately treat , basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer . 9 . Patients central nervous system ( CNS ) involvement unless meet ALL follow criterion : At least 4 week prior therapy completion ( include radiation and/or surgery ) start study treatment Clinically stable CNS tumor time screen receive steroid and/or enzymeinducing antiepileptic medication brain metastasis . 10 . Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 11 . Patient known history HIV infection chronic , active Hepatitis B ( test mandatory ) . 12 . Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , cause unacceptable safety risk , contraindicate patient participation clinical study compromise compliance protocol ( e.g . chronic pancreatitis , chronic active hepatitis , active untreated uncontrolled fungal , bacterial viral infection , etc. ) . 13 . Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality , include follow : History acute coronary syndrome ( include myocardial infarction , unstable angina , coronary artery bypass grafting , coronary angioplasty , stenting ) symptomatic pericarditis within 6 month prior screen History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) screen Clinically significant cardiac arrhythmia ( e.g . ventricular tachycardia ) , complete leave bundle branch block , highgrade Atrioventricular block ( AV ) block ( e.g . bifascicular block , Mobitz type II thirddegree AV block ) Long QT syndrome family history idiopathic sudden death congenital long QT syndrome , follow : Risk factor Torsades de Pointe ( TdP ) include uncorrected hypokalemia hypomagnesemia , history cardiac failure , history clinically significant/symptomatic bradycardia . Concomitant use medication ( ) know risk prolong QT interval and/or know cause Torsades de Pointe discontinue ( within 5 halflives 7 day prior start study drug ) replace safe alternative medication Inability determine QT interval screening ( QTcF , use Fridericia 's correction ) Systolic blood pressure ( SBP ) &gt; 160 mmHg &lt; 90 mmHg screen 14 . Patient currently receive follow medication discontinue 7 day prior start study drug ( see Table 4 detail ) : Known strong inducer inhibitor CYP3A4/5 , include grapefruit , grapefruit hybrid , pummelo , starfruit , Seville oranges That narrow therapeutic window predominantly metabolize CYP3A4/5 Herbal preparations/medications , dietary supplement . 15 . Patient currently receive receive systemic corticosteroid ≤2 week prior start study drug , fully recover side effect treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>5-FU</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>LEE011</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Refractory</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>